56 related articles for article (PubMed ID: 8835104)
1. Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors.
Li RC; Nix DE; Schentag JJ
J Chemother; 1996 Feb; 8(1):25-32. PubMed ID: 8835104
[TBL] [Abstract][Full Text] [Related]
2. The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions.
Li RC; Schentag JJ; Nix DE
Antimicrob Agents Chemother; 1993 Mar; 37(3):523-31. PubMed ID: 8460921
[TBL] [Abstract][Full Text] [Related]
3. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
Buyck JM; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity testing of Pseudomonas aeruginosa to ciprofloxacin: comparison of the modified Stokes' method with MIC results obtained by the Etest.
Galloway A; Wright J; Murphy O; Dickinson G
J Antimicrob Chemother; 1999 Feb; 43(2):314-5. PubMed ID: 11252344
[No Abstract] [Full Text] [Related]
7. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Guzel C; Savage PB; Gerceker AA
Chemotherapy; 2011; 57(6):505-10. PubMed ID: 22286090
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Solak S; Willke A; Ergönül O; Tekeli E
Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492
[No Abstract] [Full Text] [Related]
9. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.
White RL; Burgess DS; Manduru M; Bosso JA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1914-8. PubMed ID: 8843303
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
Pankey GA; Ashcraft DS
Antimicrob Agents Chemother; 2005 Jul; 49(7):2959-64. PubMed ID: 15980375
[TBL] [Abstract][Full Text] [Related]
11. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
12. Interactions of the 4-quinolones with other antibacterials.
Lewin CS; Smith JT
J Med Microbiol; 1989 Jul; 29(3):221-7. PubMed ID: 2664184
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
[TBL] [Abstract][Full Text] [Related]
14. [Effect of efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine to MIC values of ciprofloxacin in ciprofloxacin resistant gram-negative bacteria].
Coban AY; Bayram Z; Sezgin FM; Durupinar B
Mikrobiyol Bul; 2009 Jul; 43(3):457-61. PubMed ID: 19795621
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin].
Pastor A; Cantón E; Pemán J
Rev Esp Quimioter; 1998 Dec; 11(4):333-8. PubMed ID: 9990147
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility of Pseudomonas aeruginosa to ciprofloxacin in the presence of vancomycin.
Day CA; Marceau-Day ML; Day DF
Antimicrob Agents Chemother; 1993 Nov; 37(11):2506-8. PubMed ID: 8285646
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
[TBL] [Abstract][Full Text] [Related]
18. Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.
Bedard J; Chamberland S; Wong S; Schollaardt T; Bryan LE
Antimicrob Agents Chemother; 1989 Sep; 33(9):1457-64. PubMed ID: 2510591
[TBL] [Abstract][Full Text] [Related]
19. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
Parte AC; Smith JT
Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
Yasmin F; Akhtar N; Hameed A
Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
